HEADER DNA BINDING PROTEIN 19-DEC-01 1KNU TITLE LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED TITLE 2 RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 TISSUE: ADIPOSE TISSUE; SOURCE 6 GENE: PPARG, NR1C3; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 9 EXPRESSION_SYSTEM_STRAIN: BL21DE3; SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PGEX-3X-HPPARGLBD KEYWDS PPAR, NUCLEAR RECEPTOR, TRANSCRIPTION, GENE REGULATION, AGONIST KEYWDS 2 COMPLEX, DNA BINDING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR L.A.SVENSSON,S.B.MORTENSEN,J.FLECKNER,H.F.WOELDIKE REVDAT 3 11-OCT-17 1KNU 1 REMARK REVDAT 2 24-FEB-09 1KNU 1 VERSN REVDAT 1 19-DEC-02 1KNU 0 JRNL AUTH P.SAUERBERG,I.PETTERSSON,L.JEPPESEN,P.S.BURY,J.P.MOGENSEN, JRNL AUTH 2 K.WASSERMANN,C.L.BRAND,J.STURIS,H.F.WOLDIKE,J.FLECKNER, JRNL AUTH 3 A.-S.T.ANDERSEN,S.B.MORTENSEN,L.A.SVENSSON,H.B.RASMUSSEN, JRNL AUTH 4 S.V.LEHMANN,Z.POLIVKA,K.SINDELAR,V.PANAJOTOVA,L.YNDDAL, JRNL AUTH 5 E.M.WULFF JRNL TITL NOVEL TRICYCLIC-ALPHA-ALKYLOXYPHENYLPROPIONIC ACIDS: DUAL JRNL TITL 2 PPARALPHA/GAMMA AGONISTS WITH HYPOLIPIDEMIC AND ANTIDIABETIC JRNL TITL 3 ACTIVITY JRNL REF J.MED.CHEM. V. 45 789 2002 JRNL REFN ISSN 0022-2623 JRNL PMID 11831892 JRNL DOI 10.1021/JM010964G REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2000 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 39.89 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 4042063.320 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 97.3 REMARK 3 NUMBER OF REFLECTIONS : 22963 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.224 REMARK 3 R VALUE (WORKING SET) : 0.224 REMARK 3 FREE R VALUE : 0.264 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1142 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.008 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 22963 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.59 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.20 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2172 REMARK 3 BIN R VALUE (WORKING SET) : 0.3310 REMARK 3 BIN FREE R VALUE : 0.3640 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.80 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 110 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.035 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4197 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 30 REMARK 3 SOLVENT ATOMS : 32 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 49.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 57.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 2.22000 REMARK 3 B22 (A**2) : 16.18000 REMARK 3 B33 (A**2) : -18.40000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 1.16000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.34 REMARK 3 ESD FROM SIGMAA (A) : 0.33 REMARK 3 LOW RESOLUTION CUTOFF (A) : 40.0 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.42 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.42 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.270 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.870 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 3.050 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.450 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.730 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : LIG.PARAM REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN_BREAK.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : LIG.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1KNU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 27-DEC-01. REMARK 100 THE DEPOSITION ID IS D_1000015154. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 14-SEP-00 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : MAX II REMARK 200 BEAMLINE : I711 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0292 REMARK 200 MONOCHROMATOR : SAGITALLY FOCUSED SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22943 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 40.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.3 REMARK 200 DATA REDUNDANCY : 3.200 REMARK 200 R MERGE (I) : 0.07600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 13.0500 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.59 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.0 REMARK 200 DATA REDUNDANCY IN SHELL : 2.70 REMARK 200 R MERGE FOR SHELL (I) : 0.34300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.490 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNX 2000 REMARK 200 STARTING MODEL: PDB ENTRY 1PRG REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.87 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.73 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CITRIC ACID, TRIS-HCL, PH 8.0, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 294.0K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.13500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 31.72000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.13500 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 31.72000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLU A 272 REMARK 465 GLN A 273 REMARK 465 SER A 274 REMARK 465 TYR A 477 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206 REMARK 465 PRO B 269 REMARK 465 LEU B 270 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 THR B 461 REMARK 465 ASP B 462 REMARK 465 MET B 463 REMARK 465 SER B 464 REMARK 465 LEU B 465 REMARK 465 LEU B 476 REMARK 465 TYR B 477 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 206 -102.10 -68.35 REMARK 500 LYS A 240 -158.80 -77.39 REMARK 500 ASP A 243 -73.02 -47.73 REMARK 500 ASP A 260 -75.10 -67.05 REMARK 500 ILE A 262 -61.44 -104.91 REMARK 500 LYS A 263 123.63 65.24 REMARK 500 PHE A 264 49.15 -143.67 REMARK 500 LYS A 358 -55.28 -5.22 REMARK 500 LYS A 474 -120.10 -32.90 REMARK 500 LYS B 240 -9.71 -52.99 REMARK 500 PHE B 264 105.67 60.11 REMARK 500 ALA B 278 -37.98 -39.43 REMARK 500 SER B 342 67.81 37.61 REMARK 500 GLU B 343 18.66 59.14 REMARK 500 SER B 355 34.45 -68.76 REMARK 500 ARG B 357 -174.05 -52.74 REMARK 500 HIS B 425 57.44 -147.99 REMARK 500 SER B 428 78.16 -161.62 REMARK 500 LYS B 457 -19.78 -49.49 REMARK 500 LYS B 458 34.59 -72.98 REMARK 500 THR B 459 144.28 93.53 REMARK 500 TYR B 473 40.60 -99.68 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE YPA A 1001 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PRG RELATED DB: PDB REMARK 900 1PRG CONTAINS THE SAME PROTEIN. REMARK 900 RELATED ID: 2PRG RELATED DB: PDB REMARK 900 2PRG CONTAINS THE SAME PROTEIN COMPLEXED WITH BRL49653. DBREF 1KNU A 204 477 UNP P37231 PPAT_HUMAN 232 505 DBREF 1KNU B 204 477 UNP P37231 PPAT_HUMAN 232 505 SEQRES 1 A 274 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 2 A 274 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 3 A 274 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 4 A 274 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 5 A 274 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 6 A 274 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 7 A 274 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 8 A 274 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 9 A 274 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 10 A 274 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 11 A 274 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 12 A 274 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 13 A 274 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 14 A 274 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 15 A 274 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 16 A 274 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 17 A 274 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 18 A 274 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 19 A 274 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 20 A 274 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 21 A 274 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU SEQRES 22 A 274 TYR SEQRES 1 B 274 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 2 B 274 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 3 B 274 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 4 B 274 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 5 B 274 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 6 B 274 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 7 B 274 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 8 B 274 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 9 B 274 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 10 B 274 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 11 B 274 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 12 B 274 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 13 B 274 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 14 B 274 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 15 B 274 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 16 B 274 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 17 B 274 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 18 B 274 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 19 B 274 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 20 B 274 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 21 B 274 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU SEQRES 22 B 274 TYR HET YPA A1001 30 HETNAM YPA (S)-3-(4-(2-CARBAZOL-9-YL-ETHOXY)-PHENYL)-2-ETHOXY- HETNAM 2 YPA PROPIONIC ACID FORMUL 3 YPA C25 H25 N O4 FORMUL 4 HOH *32(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 ILE A 262 1 12 HELIX 4 4 GLU A 276 LYS A 301 1 26 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 SER A 332 1 23 HELIX 7 7 SER A 342 GLY A 344 5 3 HELIX 8 8 ARG A 350 LYS A 354 1 5 HELIX 9 9 PRO A 359 PHE A 363 5 5 HELIX 10 10 MET A 364 ALA A 376 1 13 HELIX 11 11 ASP A 380 LEU A 393 1 14 HELIX 12 12 ASN A 402 HIS A 425 1 24 HELIX 13 13 GLN A 430 LYS A 438 1 9 HELIX 14 14 LYS A 438 GLU A 460 1 23 HELIX 15 15 HIS A 466 LYS A 474 1 9 HELIX 16 16 GLU B 207 PHE B 226 1 20 HELIX 17 17 THR B 229 GLY B 239 1 11 HELIX 18 18 THR B 241 SER B 245 5 5 HELIX 19 19 ASP B 251 ILE B 262 1 12 HELIX 20 20 GLU B 276 SER B 302 1 27 HELIX 21 21 GLY B 305 LEU B 309 5 5 HELIX 22 22 ASP B 310 LEU B 333 1 24 HELIX 23 23 SER B 342 GLY B 344 5 3 HELIX 24 24 ARG B 350 SER B 355 1 6 HELIX 25 25 MET B 364 LEU B 377 1 14 HELIX 26 26 ASP B 380 LEU B 393 1 14 HELIX 27 27 ASN B 402 HIS B 425 1 24 HELIX 28 28 GLN B 430 LYS B 458 1 29 HELIX 29 29 HIS B 466 TYR B 473 1 8 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 4 GLY A 338 ILE A 341 -1 N VAL A 339 O MET A 348 SHEET 4 A 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 SITE 1 AC1 13 PHE A 282 CYS A 285 GLN A 286 ARG A 288 SITE 2 AC1 13 SER A 289 HIS A 323 ILE A 341 SER A 342 SITE 3 AC1 13 GLU A 343 MET A 364 HIS A 449 LEU A 469 SITE 4 AC1 13 TYR A 473 CRYST1 92.270 63.440 119.240 90.00 101.84 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010838 0.000000 0.002272 0.00000 SCALE2 0.000000 0.015763 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008569 0.00000